Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial

In BOLERO‐2, adding everolimus to exemestane resulted in a twofold increase in median progression‐free survival (PFS) vs exemestane in postmenopausal women with hormone receptor‐positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) advanced breast cancer (aBC) after progression o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesch, Hans, Stoetzer, Oliver, Decker, Thomas, Kurbacher, Christian M., Marmé, Frederik, Schneeweiss, Andreas, Mundhenke, Christoph, Distelrath, Andrea, Fasching, Peter A., Lux, Michael P., Lüftner, Diana, Hadji, Peyman, Janni, Wolfgang, Muth, Mathias, Kreuzeder, Julia, Quiering, Claudia, Taran, Florin‐Andrei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587781/
https://www.ncbi.nlm.nih.gov/pubmed/29992557
http://dx.doi.org/10.1002/ijc.31738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587781/
https://www.ncbi.nlm.nih.gov/pubmed/29992557
http://dx.doi.org/10.1002/ijc.31738

Ejemplares similares